Dr. Reddy’s Laboratories announced today that it has launched Levalbuterol Inhalation Solution in multiple dosage vials in the US market on Tuesday.
It is a therapeutic equivalent generic version of XOPENEX (levalbuterol hydrochloride) inhalation solution and approved by the United States Food & Drug Administration (USFDA). The dosages are USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials.
The Xopenex inhalation solution brand and generic combined had U.S. sales of approximately $269.7 Million MAT for the most recent twelve months ending in June 2014 according to IMS Health.
Dr. Reddy’s Levalbuterol Inhalation Solution are in Unit-Dose Vials of (5 x 3 mL) carton of 25. Levalbuterol Inhalation Solution, USP is only for use with a nebulizer, a company release said.